IDYA
6:00 AM
Catalyst Calendar
Wed, Aug 19, 2026
1 updatesTue, Aug 4, 2026
1 updatesIDYA
6:00 AM
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Presentation / Abstract • Phase 2ESMO presentation Thu, Oct 1, 2026ideayabio.com
Fri, Jul 31, 2026
1 updatesMon, Jul 27, 2026
1 updatesIDYA
6:00 AM
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
Trial Design Update • Phase 1/2Trial update Mon, Jul 27, 2026ideayabio.com
Fri, Jul 17, 2026
1 updatesIDYA
9:00 AM
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
Presentation / Abstract • Phase 2ESMO poster presentations Fri, Oct 23, 2026ideayabio.com
Fri, Jun 26, 2026
1 updatesWed, Jun 17, 2026
1 updatesMon, Jun 15, 2026
1 updatesIDYA
6:00 AM
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
Trial Start • Phase 1Trial initiation Mon, Jun 15, 2026ideayabio.com
Wed, Jun 10, 2026
1 updatesMon, Jun 8, 2026
2 updatesWed, Jun 3, 2026
1 updatesIDYA
6:00 AM
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
Trial Start • Phase 1ideayabio.com
Mon, Jun 1, 2026
1 updatesIDYA
11:00 AM
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
Presentation / Abstract • Phase 2/3Late-breaking oral presentation at ASCO Mon, Jun 1, 2026ideayabio.com